HGS and Takeda unveil targets
Takeda Chemical Industries will pursue about 100 potential drug developments from genes uncovered by Human Genome Services, Rockville, MD. The work may lead to conventional medicines and antibody based therapies for diabetes, cardiovascular disease, bone and joint disease and central nervous system disorders. Under the terms of the agreement, HGS will receive milestone and royalty payments as the drugs are clinically tested. If the medicines make the market, HGS would collect royalties equal to 'middle to high single digit' percentages of sales.